NeuroOne Medical Technologies Corporation (NMTC)
NASDAQ: NMTC · Real-Time Price · USD
0.8800
-0.0091 (-1.02%)
At close: Sep 15, 2025, 4:00 PM EDT
0.8999
+0.0199 (2.26%)
After-hours: Sep 15, 2025, 7:57 PM EDT
NMTC Revenue
NeuroOne Medical Technologies had revenue of $1.70M in the quarter ending June 30, 2025, with 105.39% growth. This brings the company's revenue in the last twelve months to $6.63M, up 69.00% year-over-year. In the fiscal year ending September 30, 2024, NeuroOne Medical Technologies had annual revenue of $3.45M with 1.33% growth.
Revenue (ttm)
$6.63M
Revenue Growth
+69.00%
P/S Ratio
4.66
Revenue / Employee
$389,944
Employees
17
Market Cap
44.00M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.45M | 45.37K | 1.33% |
Sep 30, 2023 | 3.41M | 1.29M | 60.73% |
Sep 30, 2022 | 2.12M | 1.88M | 772.60% |
Sep 30, 2021 | 242.96K | -1.68M | -87.39% |
Sep 30, 2020 | 1.93M | - | - |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NMTC News
- 7 days ago - NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025 - GlobeNewsWire
- 4 weeks ago - NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain - GlobeNewsWire
- 4 weeks ago - NeuroOne Medical Technologies Corporation (NMTC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9% - GlobeNewsWire
- 6 weeks ago - NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update - GlobeNewsWire
- 6 weeks ago - NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - GlobeNewsWire
- 7 weeks ago - NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office - GlobeNewsWire
- 3 months ago - NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System - GlobeNewsWire